JPRN-UMIN000001800已完成未知
Phase II study of irinotecan and tegafur gimeracil for NSCLC with EGFR mutation which resistant to EGFR-TKI - TS-1+CPT for EGFR-TKI resistant EGFR Mt
orth Japan Lung Cancer Study Group0 个研究点目标入组 25 人开始时间: 2010年8月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Pre-treated with 5-FU related drugs or irinotecan 2. With severe comorbidities 3. With symptomatic brain metastasis 4. Pregnant women
研究者
相似试验
已完成
1 期
Phase I/II Study of Irinotecan and Gemcitabine in Pediatric, adolescent and Young Adult Patients with Relapsed or Refractory Solid TumorsRelapse/refractory pediatric/AYA solid tumorJPRN-UMIN000020144Group for "combination chemotherapies for refractory Adolescent and Young Adult solid tumors "10
已完成
1 期
Phase I/II Trail of Gemcitabine and Irinotecan in Patients with Platinum Refractory and Resistant Ovarian cancer.Patients with platinum-refractory and &#8211resistant ovarian cancer ( including fallopian tube, primary peritoneal cancer)JPRN-UMIN000004449School of Medicine, Chiba University25
已完成
2 期
A phase II study with Tegafur/Uracil and Peg-Interferon after TACE for hepatocelluler carcinomaAdvanced hepatocellular carcinomaJPRN-C000000275The third department of Internal Medicine, Wakayama Medical University20
进行中（未招募）
1 期
A Phase I/II Trial of TG01 and Gemcitabine as adjuvant therapy for treating patients with pancreatic cancerEUCTR2012-002400-40-GBTargovax ASA32
进行中（未招募）
1 期
A Phase I/II Trial of TG01 and Gemcitabine as adjuvant therapy for treating patients with pancreatic cancerEUCTR2012-002400-40-ESTargovax AS32